Skip Navigation


Rheumatology Advance Access originally published online on August 18, 2006
Rheumatology 2006 45(10):1322; doi:10.1093/rheumatology/kel254
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
45/10/1322    most recent
kel254v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Liyanage, S. P.
Right arrow Articles by Seifert, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Liyanage, S. P.
Right arrow Articles by Seifert, M.
Related Collections
Right arrow Historical Medicine
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

OBITUARY

John H. Glyn

S. P. Liyanage1 and M. Seifert2

1Princess Margaret Hospital, Windsor, SL4 3SJ and 2St Mary's Hospital, London W2 1NY

The first 10% of the full text of this article appears below.

Formula

Corticosteroids have been the backbone of treatment of many rheumatological diseases. Most of us recognize the remarkable beneficial effects of steroids, though mindful of the potential longer-term toxicity. In 1949, Philip Hench had demonstrated the miraculous effect of cortisone at the Mayo Clinic, and he invited Will Copeman and Oswald Savage to participate in the first UK studies. The task of personally administering the first injections of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?